Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Therapeutics Development Initiative, 2009
    Validation of LRRK2 as a Drug Target for Treatment of Parkinson's Disease Using Antisense Technology

    Objective/Rationale:
    Missense mutations in leucine-rich repeat serine/threonine-protein kinase (Lrrk2) are linked/associated with dominantly inherited, late-onset Lewy body Parkinson's disease (PD)...

  • Therapeutics Development Initiative, 2009
    Pre-clinical Development of a Parkinson's Disease Therapy Using a Glucagon-Like Peptide (GLP)-1 Receptor Agonist

    Objective/Rationale:
    The Glucagon-Like-Peptide-1 (GLP-1) receptor agonist, exendin-4 (exenatide injection; brand name Byetta) is an FDA-approved, first-in-class treatment for patients with Type 2...

  • Therapeutics Development Initiative, 2009
    Distribution of a Dominant-negative Inhibitor of Tumor Necrosis Factor

    Objective/Rationale:
    The blood-brain barrier (BBB) allows only a small fraction of systemically administered small-molecule drugs and even fewer biopharmaceuticals developed for disorders of the...

  • MJFF Research Grant, 2009
    Pre-clinical Knockout Models of Parkinson's Disease

    Objective/Rationale:
    The objective of this project will be to use Sigma’s novel CompoZr (TM)  ZFN technology to genetically engineer five distinct pre-clinical models in which genes implicated in...

  • Therapeutics Development Initiative, 2009
    Optimization of Selective Mu Opioid Receptor Antagonists for the Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease

    Objective/Rationale: 
    In Parkinson’s disease, L-DOPA-induced dyskinesias (LID) are therapeutically limiting side effects that occur with long-term L-DOPA treatment, and their presence significantly...

  • Rapid Response Innovation Awards, 2009
    Identification of Nurr1 Agonists for the Treatment of Parkinson's Disease

    Objective/Rationale:
    Nurr1 is a nuclear hormone receptor strongly implicated in the growth, maintenance, and survival of dopaminergic neurons, that represents a very promising therapeutic target for...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.